KYMRHealthcare · BiotechnologyThe 24 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $127 — +26.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Accruals (34): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +26.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Deutsche Bank | Initiates | Hold | $120 |
| 28 July 2026 | Guggenheim | Maintains | Buy | $125 → $135 |
| 16 July 2026 | Mizuho | Maintains | Outperform | $120 → $140 |
| 16 July 2026 | Mizuho | Maintains | Outperform | — |
| 13 July 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 13 July 2026 | RBC Capital | Downgrade | Sector Perform | $106 → $115 |
| 30 June 2026 | B of A Securities | Maintains | Buy | — |
| 29 June 2026 | B. Riley Securities | Maintains | Buy | — |
| 29 June 2026 | Truist Securities | Maintains | Buy | — |
| 26 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 June 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Canaccord Genuity | Initiates | Buy | — |
| 16 Mar 2026 | Jefferies | Assumes | Buy | $122 → $110 |
| 3 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | Stephens & Co. | Maintains | Overweight | — |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 3 Feb 2026 | BTIG | Reiterates | Buy | — |
| 28 Jan 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 3% of US stocks
Cheaper than 19% of US stocks
Cheaper than 90% of US stocks
Higher than 88% of US stocks
Higher than 79% of US stocks
Higher than 10% of US stocks
Higher than 30% of US stocks
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYMR appears on the weeks it earns a place.
Kymera Therapeutics announced it will report its second quarter 2026 financial results on August 5, 2026, and will host a video conference call and webcast at 8:30 a.m. ET that day.
Why it matters — The earnings report and call will provide an update on Kymera's financial position and business progress for the quarter.
Kymera Therapeutics announced the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD, who will retire after eight years at the company. Dr. Rooney previously served as an immunology leader at Johnson & Johnson.
Why it matters — A KYMR watcher would care because the appointment of a new Chief Medical Officer with immunology expertise from Johnson & Johnson marks a leadership change in clinical development strategy for the company's oral immunology portfolio.
Kymera Therapeutics is advancing enrollment for KT-621 ahead of schedule, bringing pivotal atopic dermatitis data closer as the company expands its protein degrader pipeline.
Why it matters — KYMR watchers would care because progress in the KT-621 trial could represent a key development milestone for the company's pipeline in atopic dermatitis.
The 24 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $127, with estimates ranging from $97 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Kymera Therapeutics, Inc., 21 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Kymera Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +26.1% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 69 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $97 to $155 over the next 12 months.
Kymera Therapeutics, Inc. returned +133.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies.
The most recent item we track (GlobeNewsWire, 28 July 2026): "Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026". Kymera Therapeutics announced it will report its second quarter 2026 financial results on August 5, 2026, and will host a video conference call and webcast at 8:30 a.m. ET that day.
Kymera Therapeutics Inc. is a pioneering biotechnology company focused on the development of targeted protein degradation therapies. These therapies are aimed at disease-causing proteins that have traditionally been considered "undruggable." Kymera's primary function is to leverage its proprietary drug discovery platform to design small molecules that harness the cell's natural protein degradation processes, redirecting them to undesirable proteins and proteins involved in various diseases like cancer and immune-inflammatory conditions. This innovative approach holds significant promise for treating a multitude of diseases where conventional drug modalities are ineffective. Notably, Kymera's work impacts the healthcare and pharmaceutical industries by introducing novel therapeutic options and broadening the horizon for drug discovery and development. In the context of the financial market, Kymera Therapeutics represents a key player amid the emerging biotechnology companies that focus on cutting-edge science to address unmet medical needs. As such, it has captured the interest of stakeholders within both the investment community and the healthcare sector, highlighting its potential role in revolutionizing treatment paradigms on a global scale.
CEO Dr. Nello Mainolfi M.D., Ph.D. · 253 employees · United States · https://www.kymeratx.com